Real-time insights. Smarter decisions. Better trades.
🔍 Search Stocks 14 day Free Trial
EBOS GROUP LIMITED (EBO)ASX AI Signals has generated 3 signal for EBO during the last 90 days, indicating active trading activity and ongoing AI monitoring
Latest EBO Signals | |
| 19/05/2026 | SELL |
| 15/05/2026 | SELL |
| 23/04/2026 | SELL |
EBO Share Price | |
| Current Price | $17.470 |
| 52 Week High | $36.502 |
| 52 Week Low: | $15.830 |
| Trading at (% of 52 Week High) | 47.86% |
EBOS Group Limited (ASX: EBO) is a leading healthcare company based in Australia and New Zealand. It supplies pharmaceuticals, medical devices, and related products to hospitals, pharmacies, and other healthcare providers. The company also offers various healthcare and animal care services across its markets.
The Health Care Equipment & Services sector on the ASX includes companies that produce medical devices, equipment, and supplies, as well as those providing healthcare-related services. This sector covers a wide range of products such as surgical instruments, diagnostic machines, and health monitoring devices. It also includes businesses involved in healthcare management, medical laboratories, and support services. These companies play a key role in supporting hospitals, clinics, and other healthcare providers to improve patient care. The sector is influenced by factors like technological advances, regulatory changes, and demand for healthcare services.
The SELL recommendation for EBOS Group Limited is supported by moderate technical and fundamental signals indicating potential downside risk. However, the company's stable market position and consistent earnings growth temper the conviction level.
This article first appeared on GuruFocus.
Revenue: Increased 13% to $6.8 billion. Underlying EBITDA: Increased 3.2% to $300 million. Healthcare EBITDA: Up 1.3% to $254 million. Animal Care EBITDA: Grew 15.1% to $68 million. Underlying NPAT: $125 million, down slightly due to DC capital renewal prog As global markets grapple with economic uncertainty and inflation concerns, investors are increasingly looking towards Asia for opportunities, particularly in the realm of dividend stocks. In this environment, a strong dividend yield can provide a buffer against market volatility and offer a steady With its stock down 11% over the past month, it is easy to disregard EBOS Group (NZSE:EBO). However, the company's fundamentals look pretty decent, and long-term financials are usually aligned with future market price movements. Specifically, we decided to study EBOS Group's ROE in this article.
R The board of EBOS Group Limited (NZSE:EBO) has announced that it will pay a dividend of A$0.5951 per share on the 21st of March. Based on this payment, the dividend yield on the company's stock will be 3.2%, which is an attractive boost to shareholder returns.
View our latest analysis for EBOS Grou Shareholders might have noticed that EBOS Group Limited (NZSE:EBO) filed its interim result this time last week. The early response was not positive, with shares down 6.7% to NZ$39.00 in the past week. Results overall were respectable, with statutory earnings of AU$1.42 per share roughly in line witLatest EBOS GROUP LIMITED(EBO) News
Ebos Group Ltd (ASX:EBO) Half Year 2026 Earnings Call Highlights: Strong Revenue Growth Amidst ...
3 Asian Dividend Stocks Yielding Over 3.1%
Declining Stock and Decent Financials: Is The Market Wrong About EBOS Group Limited (NZSE:EBO)?
EBOS Group (NZSE:EBO) Has Announced A Dividend Of A$0.5951
Earnings Update: EBOS Group Limited (NZSE:EBO) Just Reported Its Half-Yearly Results And Analysts Are Updating Their Forecasts
Get access to daily BUY & SELL signals, advanced AI analysis, watchlists and email alerts.
14 Day Free Trial • Cancel Anytime • Founders Price $15/month
Start My Free Trial